Special issue

J.J. Breeksema, R.A. Schoevers, E. Vermetten, R. Van, M. Destoop, T. Birkenhäger, W. van den Brink

Wetenschapsnieuws

Psychedelica

Wekelijks verschijnen er talloze nieuwe publicaties in de wetenschappelijke psychiatrie-vakbladen. Voor de psychiater (i.o.) uit de dagelijkse praktijk maakt het Tijdschrift voor Psychiatrie in deze rubriek een selectie van recent verschenen publi...Read more

Effectivity of psychedelics in the treatment of psychiatric disorders; introduction

W. van den Brink, R.A. Schoevers, E. Vermetten, R. Van, J.J. Breeksema

Psychedelics in the treatment of depression, anxiety, and obsessive-compulsive disorder

J.J. Breeksema, W. van den Brink, J.K.E. Veraart, S.Y. Smith-apeldoorn, E. Vermetten, R.A. Schoevers

background There is a need for new, effective treatments for patients with (treatment-resistant) depressive disorders, anxiety disorders and obsessive-compulsive disorder (ocd). At the same time, there is renewed interest in psychedelics for the ...

Ketamine as an anesthetic, analgesic and antidepressant

S.Y. Smith-apeldoorn, J.K.E. Veraart, J. Kamphuis, J.J. Breeksema, W. van den Brink, M. Aan het rot, R.A. Schoevers

background Treatment-resistance occurs in about 30% of patients with depression. Therefore, there is an urgent need to identify new treatment strategies. Ketamine, originally developed as an anesthetic, is studied and applied as treatment for pat...

Psychedelics in the treatment of PTSD

E. Vermetten, E. Krediet, T. Bostoen, J.J. Breeksema, R.A. Schoevers, W. van den Brink

background Posttraumatic stress disorder (ptsd) is often a chronic condition, despite the availability of various evidence-based treatment options. Psychedelics offer new treatment opportunities.
aim An overview of the current evidence, thera...

Psychedelics in the treatment of substance use disorders and psychosis

W. van den Brink, J.J. Breeksema, E. Vermetten, R.A. Schoevers

background After psychedelics were banned in 1968, the flourishing research on the use of psychedelics in patients with a mental disorder stopped abruptly. Recently, we see a renaissance of this research.
aim To present an overview of what is...

Psychedelics for existential distress in terminally ill patients

N. Schimmel, J.J. Breeksema, J.K.E. Veraart, W. van den Brink, R.A. Schoevers

background Existential distress in patients with a terminal illness is often associated with (symptoms of) anxiety and depression. Psychotherapeutic interventions seem effective but effects are short-lived. There are no proven effective pharmacol...

Microdosing with psychedelics: what do we know?

K.P.C. Kuypers

background The repeated use of small doses of psychedelics such as psilocybin and lsd over a period of time (microdosing, md) has gained popularity and scientific attention in recent years. Retrospective reports from users suggest clinical potent...

Neuroscientific and psychological explanations for the therapeutic effects of psychedelics

M. van Elk

background Psychedelics have a strong therapeutic potential for the treatment of biomedical disorders, but the working mechanisms underlying psychedelics are only poorly understood.
aim To discuss different mechanisms underlying the therapeut...

Epidemiology of hallucinogenic drug use in the Netherlands

M.W. van Laar, C.J.A. van Miltenburg

background In recent years there was a renewed interest in psychedelic substances.
aim To present an overview of what is known about the use of classic psychedelic drugs and ‘atypical’ psychedelic drugs (i.e. entactogen/empathogenic drugs lik...

Recreative ecstasy use in the Netherlands: use characteristics, health risks and criminality

J. van Amsterdam, W. van den Brink

background Ecstasy (mdma) is used by approximately 370,000 Dutch people yearly, mainly young adults with a good education.
aim To describe ecstasy-related negative health effects, health risks, use profiles and crime based on data from scient...

From Adam to ecstacy; legal use of MDMA in the 1970s and 1980s

G. Blok

background mdma is currently a controversial psychedelic in the Netherlands: it is banned under the Opium Act, but widely used as a recreational drug. According to the government, the normalization of mdma must be combated, others argue in favour...

The rise, fall, and possible rise of LSD

S. Snelders, T. Pieters

background lsd and other hallucinogens or psychedelics have been therapeutically used in psychiatry in the period between the Second World War and the late 1980s. In the past years renewed interest in the medical sciences for research and therape...

Psychedelics in Western culture: unnecessary psychiatrisation of visionary experiences

W.J. Hanegraaff

background Historical research about the use of psychedelics in specific religious contexts can provide rational explanations for visionary experiences that could otherwise be cause to question the mental health of religious actors. Reversely, if...

Three forms of Dionysus: recreational, medical and religious use of ayahuasca

A. van der Braak

background Ayahuasca is a psychoactive tea that is rapidly gaining in popularity. Its effects are, however, widely different in various sets and settings, leading to various imaginings.
aim To distinguish between the recreational, medical and...

Referaat

Ketamine bij de stoornis in alcoholgebruik